In the final part of the Radioligands session from Uromigos Live 2024, the panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2, a novel target in prostate cancer treatment. The conversation explores the challenges and opportunities associated with PSMA-directed therapies, including the management of toxicities such as xerostomia and cytopenias, the importance of adaptive dosing strategies, and the potential for long-lasting treatment effects. The session wraps up with a forward-looking view on the future of radioligand therapies in prostate cancer.
Uromigos Live 2024 Radioligands Part 5: Novel Radioligands in CRPC
By Brian Rini, MD, FASCO, Karen Autio, MD, Michael Morris, MD, Gary T. Smith, MD, Tanya Dorff, MD - Last Updated: October 29, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.